

Press Release

FOR IMMEDIATE RELEASE

CRITICAL OUTCOME TECHNOLOGIES INC. DELIVERING PODIUM PRESENTATION ON NEW MECHANISM OF ACTION DATA FOR COTI-2

London, Ontario (September 28, 2012): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT), announced today that Dr. Wayne Danter, COTI's CEO and CSO, will be delivering a podium presentation at Discovery on Target: Targeting PI3K Pathways held at the Copley Marriott Hotel in Boston, MA on Tuesday, October 2, 2012 at 4:15 p.m. EDT. The presentation is entitled, *P53 Mutation Status is a Key Determinant of In Vitro Response to COTI-2, a Highly Effective Third Generation Thiosemicarbazone for the Treatment of Susceptible Cancers.*

This presentation will highlight the scientific results from recent experiments which broaden the understanding of the mechanism of action (MOA) of the Company's lead asset, COTI-2. These results demonstrate COTI-2's ability to effectively treat cancer cell lines with p53 mutations in addition to the previous preclinical MOA work showing COTI-2 to be a modulator of the PI3K/AKT/mTOR pathway. "This presentation affords us the opportunity to update a targeted scientific audience of key influencers from many partnering organizations on our improved understanding of COTI-2's unique MOA and share our insights into the potential for COTI-2," said Dr. Danter. "I am delighted to have the opportunity to share with this audience the exciting results of our most recent experiments. These experiments help to clarify some of the positive results we have seen in previous experiments that were not explained by AKT modulation alone. They also further highlight the potential of COTI-2 as a highly selective and well tolerated targeted oncology therapy candidate."

COTI-2's specific cellular targeting, low toxicity, and proven efficacy support a potentially dramatic change in the treatment of cancers with mutations of the p53 gene and/or that over express AKT/AKT2. Mutations of the p53 gene occur in at least 50% of human cancers. Over expression of AKT/AKT2 is also common in a broad range of human cancers, including colorectal, lung, ovarian, endometrial, pancreatic and breast. The percent of tumors producing excess active AKT/AKT2 ranges from 20 to 100%, depending on the cancer type. COTI-2 is the most advanced compound in COTI's pipeline discovered through CHEMSAS®, a proprietary artificial intelligence platform.

About Critical Outcome Technologies Inc.

COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling these new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with high probability of being successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com or contact:

Dr. Wayne Danter, President and CEO

wdanter@criticaloutcome.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.